Significant EBITDA Growth
Fevertree delivered almost 80% EBITDA growth, indicating strong margin recovery.
U.S. Market Performance
The brand delivered double-digit growth at constant currency in the U.S., outpacing the total mix of category by about 10%.
Gross Margin Improvement
Improved gross margin by 520 basis points year-on-year during H1, with an expectation of 600 basis points improvement across the full year.
Rest of the World Growth
Delivered a 56% increase in revenue year-on-year in the Rest of the World region, with strong performance in Canada and Australia.
Non-Tonic Product Growth
Non-tonic products have grown by 24% CAGR over the last 6 years, now making up 40% of sales.